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Background: The epidemiology of aminoglycoside-associated acute kidney injury (AG-AKI) has not been well described in pediatric patients with
cystic ﬁbrosis (CF). We aimed to assess the impact of daily serum creatinine (SCr) measurement on detection of AG-AKI at our institution.
Methods: We examined a cohort of hospitalized patients with CF who received an intravenous (IV) aminoglycoside for ≥3 days. We compared the
rate, timing, and medical management surrounding detection of AG-AKI during 2 periods: January 2010–May 2011 (Era 1, SCr measured at the
discretion of the medical team, N = 124) and June 2011–June 2012 (Era 2, SCr measured daily, N = 103). Our primary outcome was detection of AG-
AKI deﬁned as ≥50% increase in SCr from baseline (lowest value in prior 6 months), or ≥0.3 mg/dL rise within 48 h, occurring after day 2.
Results: The use of once daily tobramycin (p = 0.02) and IV ﬂuids (p b 0.001) was higher during Era 2, while AG courses were shorter (p = 0.04),
and fewer concomitant nephrotoxins (p = 0.04) were given; higher daily tobramycin doses (p b 0.001) were administered. Although the rate of
AG-AKI was not signiﬁcantly different (12% during Era 1 vs. 20% during Era 2, p = 0.09), the number of AG-AKI days detected increased (5.5
vs. 2.9 per 100 AG days, p = 0.003), and detection occurred earlier (median 6 vs. 9 days, log rank test p = 0.02) during the daily SCr period.
Conclusions: Daily SCr measurement promoted earlier and increased detection of AG-AKI in patients with CF at our institution. We suggest
systematic evaluation for AKI during aminoglycoside administration in patients with CF.
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creatinine; SD, standard deviation.
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Acute kidney injury (AKI) is defined as an acute decrease in
kidney function and clinically characterized by an increase in
serum creatinine (SCr) or a decrease in urine output.
Nephrotoxic medication exposure represents a common cause
of AKI in hospitalized children, accounting for 16% of AKI [1].
Acute kidney injury secondary to aminoglycoside use occurs
due to accumulation of the drug within the renal proximal
tubule epithelial cells [2], develops during 24–30% of AG
courses lasting 5 or more days in non-critically ill children,ll rights reserved.
Table 1
Nephrotoxic medications collected during chart review.
Antimicrobials
Antifungals Antivirals Antibacterials
Amphoteracin B (liposomal) Acyclovir Cefotaxime
Amphoteracin B Cidofovir Ceftazidime
Foscarnet Cefuroxime
Ganciclovir Colistin
Valacylovir Dapsone
Valganciclovir Nafcillin
Piperacillin/
Tazobactam
Ticarcillin/Clavulanate
Vancomycin
Others
Antihypertensives Immunosuppressants
and chemotherapeutics
Non-steroidal
anti-inflammatory drugs
Captopril Carboplatin Ibuprofen
Enalapril Cisplatin Ketorolac
Furosemide Cyclosporine Naproxen
Ifosfamide
Mesalamine
Methotrexate
Sirolimus
Sulfasalazine
Tacrolimus
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Individuals who sustain AKI are also at increased risk for
increased mortality and development of chronic kidney disease
[4–7]. Even small changes in SCr of 0.3–0.5 mg/dl are
associated with worse outcomes in children and adults [8–12].
Aminoglycoside use during pulmonary exacerbations in cystic
fibrosis (CF) is common due to activity against Pseudomonas
aeruginosa, the most prevalent CF respiratory pathogen. Most
reports of AKI in patients with CF have implicated aminoglyco-
sides as the cause [13–19], and the incidence of AKI in CF is
significantly higher than in the general population [13]. However,
data on AKI in pediatric patients with CF are limited. Among
adults with CF, episodes of AKI are associated with decreased
kidney function over time [20]. Some authors have also found that
repeated intravenousAG use in patients with CF is associatedwith
long-term kidney damage [21]. Therefore, it is crucial to
accurately detect AKI among this high-risk patient population.
Traditional monitoring for AKI during AG therapy involves
non-systematic SCr measurement that is usually based on patient
physiology, past history with the medications, or clinician
preference. Non-systematic SCrmeasurement may underestimate
kidney damage in patients with CF [22] and does not accurately
characterize the prevalence of kidney injury in this population. In
June 2011, our institution implemented a hospital-wide policy
whereby all non-critically ill patients receiving aminoglycosides
for more than 3 days have SCr measured daily [23].We sought to
characterize AKI according to Kidney Disease Improving Global
Outcomes (KDIGO) criteria (see Study Definitions, [24]) during
AG administration among our CF population during two time
periods: January 2010 through May 2011 (Era 1, prior to the
implementation of routine SCr measurement) and June 2011
through June 2012 (Era 2, the period of systematic SCr
evaluation). Our goal was to determine the impact of daily SCr
measurement on AG-associated AKI detection among patients
with CF.
2. Methods
2.1. Study design
We conducted a retrospective cohort study of all hospital
admissions from January 2010 through June 2012 in patients
with cystic fibrosis during which an intravenous (IV) AG was
given for at least three consecutive days at Cincinnati
Children's Hospital Medical Center. Patients admitted to the
pediatric intensive care unit (N = 4) or neonatal intensive care
unit (N = 2) were excluded because AKI is often multifactorial
in the setting of critical illness. A prospective database
maintained by the Division of Pulmonary Medicine was used
to identify all eligible subjects. Prior to June 2011 (Era 1), SCr
was measured at the discretion of the medical team. Starting in
June 2011 (Era 2), all subjects had SCr measured daily. During
both periods, the interpretation of and response to SCr values
was left to the medical team; there were no specific
interventions implemented related to reducing AKI during
either period. We sought to assess the impact of daily SCr
measurement on aminoglycoside-associated AKI detection bycomparing AG-associated AKI among the two time periods of
our study. The study protocol was approved by our institution's
Institutional Review Board with a waiver of consent.
Medical records were reviewed to extract data including
demographic and clinical information, past medical history,
laboratory measurements, and medication and intravenous fluid
administration. A complete list of nephrotoxic medications is
listed in Table 1 [11,25]. Intravenous contrast administration was
also included as a nephrotoxin. Serum creatinine concentrations
were collected from the start of AG administration through 72 h
after completion of therapy.
2.2. Definitions
Acute kidney injury was defined as a rise in SCr by at least
50% from baseline or a rise in SCr ≥0.3 mg/dL within a 48-h
period, which was adapted from KDIGO criteria [24]. A SCr
value was only considered AKI if it was at least 0.5 mg/dL. The
severity of AKI was also assessed according to KDIGO
staging. The baseline SCr was defined as the lowest SCr
value obtained within 6 months prior to day 3 of AG course;
SCr measurements during an AG course which were lower than
the baseline were used for subsequent SCr comparisons only.
Days on which SCr was not measured were not considered AKI
days unless both the preceding and subsequent SCr measure-
ments met AKI criteria.
Hospital admissions from January 2010 to May 2011 were
classified as Era 1, while Era 2 was defined as any hospital
admission from June 2011 through June 2012. The first
calendar day of AG administration was considered day one.
Acute kidney injury prior to day 3 of AG administration may be
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measure AKI more directly attributable to AG use, only day 3
of AG therapy and beyond were regarded as “at-risk” days. Any
episode of AKI which developed on or after day 3 of AG
administration was classified as aminoglycoside-associated
AKI (AG-AKI). If AKI was present prior to day 3, subsequent
AKI was classified as AG-AKI only if the initial AKI had
resolved for at least 72 h.
Spirometry was performed on one of three flow-sensing
spirometers (Sensormedics, Yorba Linda, CA), with calibration
performed daily per American Thoracic Society recommenda-
tions. Respiratory therapists supervising the spirometry assured
that each test met all American Thoracic Society/European
Respiratory Society criteria for acceptability. All measurements
were body temperature, pressure, and saturation corrected;
normal values were based on published reference ranges
[26,27]. A subject's baseline forced expiratory volume in one
second percent of predicted (FEV1) was defined as the highest
value in the 6 months prior to admission. The admission FEV1
was based on spirometry performed within 48 h of hospital
admission. The discharge FEV1 value was based on PFTs
performed most closely preceding hospital discharge.2.3. Therapeutic drug monitoring and serum creatinine
measurement
Therapeutic drug monitoring for aminoglycosides was
routinely performed in all subjects during the study. For those
receiving once daily dosing, drug levels were obtained
following the first dose at 3 and 10 h post-infusion. For those
receiving multiple daily doses, drug levels were measured
30 min following the 3rd dose and immediately prior to the 4th
dose (trough level). Linear regression based on drug levels was
performed by clinical pharmacists to estimate an individual's
pharmacokinetic parameters and determine optimal dosing.
Additional 10 h or trough drug levels were routinely obtained
after 1 week of therapy, or sooner only if the clinical condition
of the subject changed.
Serum creatinine was measured by coupled enzymatic
reaction on the ©Siemens Dimension Vista® 1500 Chemistry
Analyzer. Serum creatinine was drawn from a central venous
catheter or peripherally-inserted central catheter when available.
Peripherally inserted central catheters were placed in all CF
patients without implanted central venous catheters receiving
antibiotics for ≥3 days as part of standard of care.2.4. Data Analysis
Each unique aminoglycoside course was included for
analysis and served as the basis for all analyses. Summary
statistics were described using means with standard deviations
or medians with interquartile ranges for non-normally distrib-
uted data. Chi-squared tests and Fisher's exact tests compared
categorical variables, as appropriate, while t-tests and Wilcoxon
rank-sum tests were used to compare continuous variables.
Kaplan–Meier survival curves were constructed to assess thetime to first AG-AKI detection; log-rank tests were used to
compare the survival distributions of the two eras.
To address the influence of multiple AG courses among
individual subjects on AG-AKI rates and changes in FEV1, we
conducted secondary analyses using repeated sampling and
meta-analysis methods. Briefly, one AG course was randomly
chosen for each unique subject in the study. Two-sample tests
of proportions compared AG-AKI rates among selected courses
between Era 1 and Era 2, and a p-value was generated.
Two-sample t-tests compared changes in FEV1 from baseline to
admission, as well as baseline to discharge, for each sampling
and derived p-values. The procedure was repeated fifty times
and the p-value recorded for each sampling. The p-values were
transformed to −2 ln(p-value), added together, and compared
with the 5% critical value coming from the lower tail of the
chi-squared distribution on 100 degrees of freedom to generate
an overall p-value (Fisher's inverse chi-squared method [28]).
Statistical analyses were performed using Stata 10.0
(StataCorp LP, College Station, TX) and R version 2.15.1
(2012-6-22, the R Foundation for Statistical Computing). Study
data were collected and managed using REDCap electronic
data capture tools hosted at Cincinnati Children's Hospital
Medical Center [29].
3. Results
During the study period, an intravenous AG was given
during 56% of all non-critically ill hospital admissions of any
cause among patients with CF. A total of 227 AG courses of
3 days or more were given to 87 unique subjects. There were
124 AG courses administered during Era 1, while 103 were
given during Era 2. The median number of AG courses per
subject in the study was two (range: 1–11), while the median
length of AG administration was 13 days (range: 3–28). Fig. 1
provides a flow diagram of AG administration and AG-AKI
detection among our study cohort.
The demographics and past medical history of the study
cohort are described in Table 2. Factors related to the medical
management of our study cohort are also detailed in the table.
One course of amikacin was administered while all others were
tobramycin. Non-aminoglycoside nephrotoxins were given on
two or more days during 161 (71%) of the AG courses: 124
(55%) received one other nephrotoxin while 37 (16%) received
two or more. The non-aminoglycoside nephrotoxins most often
used were ceftazidime (24%), ticarcillin/clavulanate (18%),
non-steroidal anti-inflammatory drugs (18%), piperacillin/tazo-
bactam (16%), and vancomycin (9%); there were no significant
changes in the use of these medications during the two periods.
Aminoglycoside-associated AKI was detected during 36 of the
227 AG courses (16%) over the study period. Aminoglycoside-
associated AKI occurred at a rate of 4.0 per 100 at-risk days (95%
confidence interval 3.2–4.8) overall. Table 3 details data related to
AG-AKI during the two periods of the study.When accounting for
multiple admissions among unique subjects, differences in
AG-AKI rates between Era 1 and Era 2 remained significant
(Fisher's inverse chi-squared p b 0.001). Fig. 2 demonstrates
Kaplan–Meier estimates of survival time for first day of AG-AKI
Fig. 1. Flow diagram of aminoglycoside administration and aminoglycoside-associated acute kidney injury in patients with cystic fibrosis during the study period.
a Excluded from study. b Unable to assess AG-AKI due to lack of SCr measurements during at-risk period. All subjects assumed not to have AG-AKI for analyses.
Abbreviations: AG, aminoglycoside; AG-AKI, aminoglycoside-associated acute kidney injury; CF, cystic fibrosis; SCr, serum creatinine.
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two time periods of the study (log rank p = 0.02). No patients
required dialysis during the study.
Serum creatinine was measured on or after day 3 in 96
(78%) Era 1 AG courses compared with all in Era 2
(p b 0.001). In Era 1, SCr was not measured during the
3 days preceding the first day of AG-AKI detection in ten
(67%) individuals with AG-AKI compared with zero during
Era 2 (p b 0.001). Six (40%) subjects in Era 1 with AG-AKI
did not have SCr measured during the 3 days following
AG-AKI detection (zero during Era 2, p = 0.002). Serum
creatinine was measured on 19% of possible at-risk days during
Era 1 compared to 95% of at-risk days in Era 2 (p b 0.001).
Baseline and admission FEV1 values were similar during the
two time periods (Table 2), as were mean FEV1 values at
discharge. After accounting for multiple admissions among
individual subjects, Era 1 subjects had a larger decline in FEV1
from baseline to admission (Fisher's inverse chi-squared
p b 0.001). However, there was no difference in FEV1
recovery (baseline to discharge) between the two time periods
(Fisher's inverse chi-squared p = 0.95).
4. Discussion
Our study demonstrates the impact of daily serum creatinine
measurement on AG-AKI ascertainment in patients with CF
receiving tobramycin therapy. The implementation of daily SCrmeasurement as part of a hospital-wide quality initiative led to
earlier and increased detection of AG-AKI in our CF
population. Daily SCr monitoring allowed for better character-
ization of AKI timing, duration, and severity during aminogly-
coside courses than non-systematic SCr measurement.
There were no specific interventions related to the implemen-
tation of daily SCr measurement at our institution, and no policies
related to antibiotic or IV fluid prescribing were initiated. The
interpretation of SCr values and all medical decisions were left to
the medical team during both periods of the study. Despite this,
there was a clear change in the management of CF patients
receiving aminoglycosides from Era 1 to Era 2. Intravenous fluid
use increased, tobramycin was given as a single daily dose more
often, and the concomitant administration of two or more
non-aminoglycoside nephrotoxins decreased in Era 2. Amino-
glycoside courses were also shorter, which was not the result of
more frequent use of home IV antibiotics. Therefore, changes in
practice likely resulted from increased awareness of the
nephrotoxic potential of aminoglycosides and appreciation for
AG-AKI in our CF population. Importantly, we detected no
differences in pulmonary outcomes during the two time periods
of the study. The implementation of daily SCr monitoring, and
the resultant changes to clinical practice that followed, did not
impair subjects' overall lung function recovery.
Traditional monitoring for AKI has involved periodic
measurement of SCr during aminoglycoside courses based on
caregiver-specific practice patterns. Prior to the implementation
Table 2
Demographics, past medical history, pulmonary function testing, and hospital management among subjects receiving aminoglycoside courses over the study. a
Variable Era 1 (January 2010–May 2011, N = 124) Era 2 (June 2011–June 2012, N = 103) p-value
Demographics
Female gender, N (%) 65 (52) 57 (55) 0.66
Caucasian, N (%) 122 (98) 101 (98) 0.85
Age in years, N (%)
b9 10 (8) 11 (11) 0.70
9–12 19 (15) 20 (19)
13–16 27 (22) 21 (20)
17–20 59 (48) 41 (40)
≥21 9 (7) 10 (10)
Past medical history
CF-related diabetes, N (%) 80 (65) 69 (67) 0.70
History of AKI at any time prior to admission, N (%) 65 (52) 54 (52) 1.0
AKI within 90 days prior to admission, N (%) 22 (18) 14 (14) 0.39
Aminoglycoside receipt within 90 days prior to admission, N (%) 39 (32) 32 (31) 0.95
Number of inpatient aminoglycoside courses in 5 years
prior to admission, median (IQR)
5.5 (2–8) 4 (2–8) 0.10
Baseline SCr in mg/dL, mean (SD) 0.52 (0.13) 0.52 (0.17) 0.88
AKI within first 2 days of aminoglycoside course, N (%) 6 (5) 8 (8) 0.42
Pulmonary function testing
Baseline FEV1 percent predicted
b, Mean (SD) 79.2 (25.5) 79.9 (22.9) 0.84
Admission FEV1 percent predicted
c, Mean (SD) 64.3 (22.3) 64.5 (21.7) 0.95
Discharge FEV1 percent predicted
d, Mean (SD) 76.3 (23.5) 76.5 (22.9) 0.95
Hospital management
Duration of aminoglycoside therapy in days, Median (IQR) 13 (8-14.5) 11 (7–14) 0.04
Tobramycin dose in mg/kg/day, Mean (SD) 10.1 (1.6) 10.8 (1.5) b0.001
Receipt of once-daily tobramycin e, N (%) 72 (58) 75 (73) 0.02
Receipt of overnight or continuous IV fluids e, N (%) 18 (15) 44 (43) b0.001
Receipt of 2+ concomitant nephrotoxins f, N (%) 26 (21) 11 (11) 0.04
Discharged to complete IV antibiotics at home, N (%) 33 (27) 30 (29) 0.67
Abbreviations: AKI, acute kidney injury; CF, cystic fibrosis; FEV1, forced expiratory volume in 1 second; IQR, interquartile range; SCr, serum creatinine; SD,
standard deviation.
a Individual aminoglycoside courses serve as the denominator for all calculations and comparisons made in the table.
b Baseline deﬁned as the highest value in the 6 months prior to the start of the AG course; data available for 113 subjects in Era 1 (91%) and 88 in Era 2 (85%, p = 0.18).
c Admission FEV1 deﬁned as value obtained within 48 h of admission; data available for 95 subjects in Era 1 (77%) and 81 in Era 2 (79%, p = 0.72).
d Discharge FEV1 deﬁned as value obtained closest to and preceding discharge; data available for 103 subjects in Era 1 (83%) and 82 in Era 2 (80%, p = 0.50).
e Administered on all days of the AG course.
f Administered on at least 2 days during AG course.
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SCr measured on admission and then once weekly during the
aminoglycoside course, unless there was a significant clinical
change (decreased urine output, etc.). The detected rate ofTable 3
Aminoglycoside-associated acute kidney injury over the study period.
Variable Er
Aminoglycoside-associated AKI, N (%) 15
Days of AG-AKI per 100 at-risk AG days a, mean (95% CI) 2.9
First day of AG-AKI detection, median (range) 9 (
Maximal severity of AKI b
KDIGO stage 1, N (%) 12
KDIGO stage 2, N (%) 3 (
KDIGO stage 3, N (%) 0
Abbreviations: AG, aminoglycoside; AG-AKI, aminoglycoside-associated acute kidn
Outcomes; 95% CI, 95% confidence interval.
a At-risk days deﬁned as all AG days beyond day 3 of therapy. Conﬁdence interv
b Percentages displayed and comparisons made among those with AG-AKI only.
48 h, stage 2 = SCr 2.0–2.9 times baseline, and stage 3 = SCr ≥3 times baseline.AG-AKI was nearly 50% lower in Era 1 compared to Era 2 of
our study, and this difference was statistically significant even
when multiple admissions were taken into account. Our
findings are similar to previous studies that have shown thata 1 (N = 124) Era 2 (N = 103) p-value
(12) 21 (20) 0.09
(2.0-3.9) 5.5 (4.0-7.0) 0.003
3–16) 6 (3–15) 0.02
(80) 17 (81) 0.64
20) 3 (14)
1 (5)
ey injury; AKI, acute kidney injury; KDIGO, Kidney Disease Improving Global
als calculated using two sample test of proportions.
KDIGO stage 1 = SCr 1.5–1.9 times baseline or ≥0.3 mg/dL increase within
Fig. 2. Kaplan–Meier survival analysis for time to first day of AG-AKI detection.
The two time periods of the study were compared (log rank p = 0.02); period of
observation 3-28 days.
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the true AKI rate during AG courses in non-critically ill
children [3]. In patients with cystic fibrosis, who often receive
numerous lifetime courses of AG therapy, accurate AKI
ascertainment (detection, classification) is crucial to minimize
the ramifications of repeated AG therapy and of episodes of
AKI on short- and long-term outcomes.
We are limited in our ability to draw definitive conclusions
about the true rate of AG-AKI in Era 1. Non-systematic SCr
monitoring restricted our ability to accurately characterize the
timing and duration of AKI during this earlier time period. One in
five subjects had no SCr measurements after day 3, while two
thirds of Era 1 subjects with AG-AKI did not have SCr measured
in the 3 days preceding AKI detection. We assumed all patients
without SCr measurements did not have AKI, which likely
underestimates days of AKI. With an increased use of
nephrotoxic medications, longer AG courses, and less frequent
IV fluid use during Era 1, it is possible that the actual rate of
AG-AKI was even higher than that observed during Era 2,
although this cannot be confirmed. We believe that the continued
performance of daily SCr monitoring is a simple and important
tool to accurately capture episodes of AKI in our high-risk CF
population.
There are additional limitations to this study. This was a
retrospective study which relied on chart review and data
collection was limited to information available in each subject's
electronic medical record. However, most of the data that were
collected for our study were laboratory and pharmacy data,
which are subject to less confirmation bias than abstraction of
data from medical histories or physical examinations. Second,
our study focused on the detection of AKI through measure-
ment of serum creatinine, which is known to be an unreliable
index of renal function in patients with CF [22]. Serum
creatinine is an insensitive marker of kidney injury and a
demonstrable change in SCr does not occur until significant
renal mass has been affected [30]. In patients with CF, SCr
values may be lower compared to other populations owing to
reduced muscle mass and values may be normal even whenglomerular filtration rate is reduced [21]. It is therefore possible
that even with daily SCr measurement our findings underesti-
mate true kidney injury sustained. Additional studies are
needed to define the ideal biomarker(s) for kidney injury in
cystic fibrosis patients. Finally, our study was not designed to
assess the impact of AKI on outcomes among our cohort.
Traditional outcome measures in studies of AKI (length of stay,
hospital costs) are not ideal in patients with CF whose hospital
stays are often dependent on multiple factors: lung function
recovery, weight gain, compliance with home therapies, and
others. Additional prospective studies are needed to address the
impact of AKI on long-term outcomes in CF patients and
identify risk factors for AG-AKI in this population.
Our study demonstrates that the implementation of daily SCr
monitoring during aminoglycoside courses allowed for earlier
and more accurate detection of AG-AKI in our CF population.
As more data becomes available about the short- and long-term
ramifications of AKI in CF patients, precise characterization
and detection of AKI will be paramount. Systematic SCr
monitoring may also promote early intervention to mitigate
AKI when non-aminoglycoside antibiotic options are limited.Conﬂicts of interest
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